Short-term Outcomes of Trabeculectomy with Mitomycin-C in a Tertiary Eye Hospital in Nepal: A Prospective Descriptive Study

Objective This study evaluated the short-term outcomes of trabeculectomy with mitomycin-C in glaucoma patients at Tilganga Institute of Ophthalmology, Kathmandu, Nepal, between June 2021 and May 2022.

This was a prospective descriptive study, conducted on 56 eyes of 51 consecutive glaucoma patients who underwent trabeculectomy with mitomycin-C (0.02%). Follow-up assessments were carried out on postoperative day 1, week 1, month 1, month 3, and month 6. Statistical analysis was done using SPSS version 20 software.

The study included 38 male (74.5%) and 13 female (25.5%) patients with an average age of 43.50 ± 15.45 years. A significant reduction in median intraocular pressure (IOP) from 24.33 mmHg preoperatively to 12.00 mmHg at 6 months postoperatively was observed (P < 0.01). The median number of anti-glaucoma medications decreased from 3.0 preoperatively to 0.0 at all postoperative visits. Complete surgical success was achieved in 85.7% of eyes. Common complications included shallow anterior chamber, hypotony, and IOP elevation.

Trabeculectomy with mitomycin-C demonstrated high surgical success rate with low complication rates in the short term, making it an effective and safe treatment option for glaucoma patients not medically controlled. It may benefit glaucoma patients facing challenges with long-term anti-glaucoma medication use and frequent follow-up visits, thus improving the management outcomes of this chronic condition. Competing Interest Statement The authors have declared no competing interest. Funding Statement The author(s) received no specific funding for this work. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical approval for this study was obtained from IRB of National Academy of Medical Sciences, Bir Hospital, Mahaboudha, Kathmandu, Nepal with approval number Ref. No.: 136612078179 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All relevant data are within the manuscript and its Supporting Information files.